Platform Improvements Sample Clauses
Platform Improvements. Senti shall own all rights, title and interest in all Program IP that is [***] the Senti Platform that was disclosed by Senti to BlueRock prior to such Program IP being generated or developed (“Senti Platform Improvements”); provided that Senti Platform Improvements shall [***]. BlueRock shall assign and hereby assigns to Senti all of BlueRock’s right, title and interest in and to all Senti Platform Improvements. Senti hereby grants to BlueRock a non-exclusive, royalty-free, fully paid, perpetual, irrevocable, sublicensable, worldwide license to any Senti Platform Improvement generated or developed by or on behalf of BlueRock that [***]. BlueRock shall own all rights, title and interest in all Program IP that is [***] the BlueRock Platform that was disclosed by BlueRock to Senti prior to such Program IP being generated or developed (“BlueRock Platform Improvements”). Senti shall assign and hereby assigns to BlueRock all of Senti’s right, title and interest in and to all BlueRock Platform Improvements. Program IP that relates to both the Senti Platform and the BlueRock Platform, and that cannot be separated into Program IP that solely relates to the Senti Platform and Program IP that solely relates to the BlueRock Platform, shall be deemed “Other Program IP” in accordance with Section 6.1(b)(iii).
Platform Improvements. Notwithstanding the foregoing (a) as between the Parties, TScan shall solely own all right, title and interest in and to TScan Platform Improvements; and (b) TScan Platform Improvements shall not be considered Collaboration Technology.
Platform Improvements. As between the Parties, each Party will exclusively own all improvements, modifications and enhancements to (i) in the case of AstraZeneca, the AstraZeneca Pipeline or the AstraZeneca Conjugation Chemistry Platform Controlled by AstraZeneca, together with any intellectual property rights therein or thereto (collectively with the AstraZeneca Patents and AstraZeneca Know-How, the “AstraZeneca Background IP”) and (ii) in the case of Fusion, the Fusion Alpha Emitting Platform, Fusion Manufacturing Platform, each Controlled by Fusion, or Fusion Pipeline, together with any intellectual property rights therein or thereto (collectively with the Fusion Patents and Fusion Know-How, the “Fusion Background IP”), in each case, made available to a Collaboration Program, whether such improvements, modifications and enhancements are developed by either Party alone or jointly with the other Party. For clarify, any AstraZeneca Combination Collaboration Intellectual Property or AstraZeneca Sole Step In Trial IP developed under this Agreement and disclosing a compound from the AstraZeneca Pipeline, or the molecular target thereof, shall be solely owned by AstraZeneca.
Platform Improvements. (a) [***].
(b) [***].
(c) [***].
(d) [***].